Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment

You, Shijing; Han, Xiahui; Xu, Yuance; Yao, Qin

doi:10.1007/s00726-023-03313-1

Cited by 5 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous case of bioinformatics analysis, it was found that GNAL was low-expressed in gliomas, and it could be used as a protective factor for gliomas [23] , this result is consistent with our research, and it is also one of the potential sites for future targeting research. SLC7A14 is considered to be a group of transmembrane transporters, which is essential for arginine transport in mammals [24] . However, unfortunately, this gene has not been reported in tumors, and in our study, its expression in tumor tissues is decreased, so it may be involved in the regulation of glioma occurrence and development as a protective factor.…”

Section: Discussionmentioning

confidence: 99%

The prognosis model of glioblastoma was constructed based on lactic acid metabolism-related genes

Lu,

Jiang,

Zheng

et al. 2024

Preprint

View full text Add to dashboard Cite

Related studies have shown that lactate played a key role in immune escape and metastasis. Exploring the roles of lactic acid metabolism-related genes (LRGs) in glioblastoma (GBM) has great significance for clinic treatment of GBM.The target genes were obtained by intersecting the differentially expressed genes (DEGs) and the module genes. Biomarkers of GBM were screened out to construct the survival risk model, and the nomogram of GBM was constructed to clinically predict the survival of GBM patients. Moreover, the gene set enrichment analysis (GSEA) and the tumor micro-environment analysis were conducted to study the functions of different risk groups and the potential mechanism of GBM. Furthermore, the drug sensitivity analysis were carried out to provide theoretical support for clinical treatment of GBM.The risk score was constructed with six biomarkers, including CALN1, CDHR1, CRTAC1, GNAL, SLC7A14, and SPHKAP, and SLC7A14 was negative factors of GBM. Based on it, the prognostic model was constructed with age, IDH status, grade, and risk score. Noticeable, the clinical risk of GBM were associated with proliferation, migration, apoptosis, and immune related signaling pathways. In addition, the level of immune escape was higher in high risk group, and samples in high risk group were more sensitive to Vinorelbine_2048, Paclitaxel_1080, Docetaxel_1007, Gefitinib_1010, Erlotinib_1168, and etc. drugs. In this study, we identified six LRGs, including CALN1, CDHR1, CRTAC1, GNAL, SLC7A14, and SPHKAP. These findings might help to deepen the understanding of the regulatory mechanism of LRGs in GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognosis model of glioblastoma was constructed based on lactic acid metabolism-related genes

Lu,

Jiang,

Zheng

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In conclusion, SLC7A1 is a strong potential therapeutic target for HGSOC, but there is no clear target for SLC7A1. Considering that SLC7A1 mainly ingests arginine, most of the drugs currently available target energy depletion of arginine 52 . It is worth noting that arginine depletion is a double‐edged sword in the tumor microenvironment, and its therapeutic effect in solid tumors, especially ovarian cancer cells, needs further research.…”

Section: Discussionmentioning

confidence: 99%

High expression of SLC7A1 in high‐grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT

You,

Han,

et al. 2024

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

Our previous studies have shown that upregulation of SLC7A1 in epithelial ovarian cancer (EOC) tumor cells significantly increases cancer cell proliferation, migration, and cisplatin resistance; however, the molecular mechanism by which SLC7A1 functions in EOC remains unknown. In later studies, we found that SLC7A1 is also highly expressed in the interstitial portion of high‐grade serous ovarian cancer (HGSOC), but the significance of this high expression in the interstitial remains unclear. Here, we showed the Interstitial high expression of SLC7A1 in HGSOC by immunohistochemistry. SLC7A1 enriched in cancer‐associated fibroblasts (CAFs) was upregulated by TGF‐β1. Transwell assay, scratch assay, cck8 assay and cell adhesion assay showed that SLC7A1 highly expressed in CAFs promoted tumor cells invasion, migration and metastasis in vitro. The effect of SLC7A1 on MAPK and EMT pathway proteins in ovarian cancer (OC) was verified by RNA sequencing and western blotting. Overexpression of SLC7A1 in OC is involved in MAPK/ ERK pathway and EMT. In general, in HGSOC, CAFs overexpressing SLC7A1 supported the migration and invasion of tumor cells; SLC7A1 is highly expressed in ovarian cancer and is involved in ERK phosphorylation and EMT signaling in MAPK signaling pathway. This suggests that SLC7A1 may be a potential therapeutic target for OC metastasis.

show abstract

“…It has recently been shown to be an important tumor promoter in pancreatic cancer [ 7 ]. The cationic amino acid transporter (CAT, SLC7A1-4, and SLC7A14) family has also gained interest in the field of cancer research, especially for their role in arginine transport and the importance of arginine in the tumor microenvironment [ 273 ].…”

Section: Future Perspectives and Concluding Remarksmentioning

confidence: 99%

Exploring Amino Acid Transporters as Therapeutic Targets for Cancer: An Examination of Inhibitor Structures, Selectivity Issues, and Discovery Approaches

Jakobsen,

Nielsen

2024

Pharmaceutics

View full text Add to dashboard Cite

Amino acid transporters are abundant amongst the solute carrier family and have an important role in facilitating the transfer of amino acids across cell membranes. Because of their impact on cell nutrient distribution, they also appear to have an important role in the growth and development of cancer. Naturally, this has made amino acid transporters a novel target of interest for the development of new anticancer drugs. Many attempts have been made to develop inhibitors of amino acid transporters to slow down cancer cell growth, and some have even reached clinical trials. The purpose of this review is to help organize the available information on the efforts to discover amino acid transporter inhibitors by focusing on the amino acid transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), xCT (SLC7A11), SNAT1 (SLC38A1), SNAT2 (SLC38A2), and PAT1 (SLC36A1). We discuss the function of the transporters, their implication in cancer, their known inhibitors, issues regarding selective inhibitors, and the efforts and strategies of discovering inhibitors. The goal is to encourage researchers to continue the search and development within the field of cancer treatment research targeting amino acid transporters.

show abstract

Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment

Cited by 5 publications

References 87 publications

The prognosis model of glioblastoma was constructed based on lactic acid metabolism-related genes

The prognosis model of glioblastoma was constructed based on lactic acid metabolism-related genes

High expression of SLC7A1 in high‐grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT

Exploring Amino Acid Transporters as Therapeutic Targets for Cancer: An Examination of Inhibitor Structures, Selectivity Issues, and Discovery Approaches

Contact Info

Product

Resources

About